Patent · US Active

Micro-RNA signatures for the prediction of liver dysfunction

US11339440B2 · kind B2 · utility

0Cited by

17References

13Claims

0Family size

Assignees

TAmiRNA GmbH · AT
Medizinische Universität Wien · AT

Inventors

Matthias Hackl · Bisamberg, AT
Alice Assinger · Wien, AT
Patrick Starlinger · Wien, AT

Key dates

Filing date	Sep 20, 2019
Grant date	May 24, 2022
Priority date	—
Expiry date	Sep 20, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q2600/178
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The invention relates to an in vitro method of determining a subjects risk of liver dysfunction, specifically after partial liver resection, said method comprising the steps of providing a sample from said subject, determining in said sample the expression level of at least one miRNA, selected from the group consisting of miR-151a, miR-192 and miR-122, and comparing these expression level(s) with at least one reference expression level, or identifying the ratios of the expression levels of miR-15 la to miR-192 and/or of miR-122 to miR-151a and comparing said expression level ratios with reference expression level ratios, and classifying the sample from the outcome of the comparison into one of at least two classes, wherein each class is one of the at least two categories “high-risk” and “low-risk”.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.